TY - JOUR AU - Postow, M. A. AU - Callahan, M. K. AU - Wolchok, J. D. PY - 2015 DA - 2015// TI - Immune checkpoint blockade in Cancer therapy JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.4358 DO - 10.1200/JCO.2014.59.4358 ID - Postow2015 ER - TY - JOUR AU - Ribas, A. AU - Wolchok, J. D. PY - 2018 DA - 2018// TI - Cancer immunotherapy using checkpoint blockade JO - Science. VL - 359 UR - https://doi.org/10.1126/science.aar4060 DO - 10.1126/science.aar4060 ID - Ribas2018 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Fecher, L. A. AU - Agarwala, S. S. AU - Hodi, F. S. PY - 2013 DA - 2013// TI - Ipilimumab and its toxicities: a multidisciplinary approach JO - Oncologist. VL - 18 UR - https://doi.org/10.1634/theoncologist.2012-0483 DO - 10.1634/theoncologist.2012-0483 ID - Fecher2013 ER - TY - JOUR AU - Chang, L. S. AU - Barroso-Sousa, R. AU - Tolaney, S. M. PY - 2019 DA - 2019// TI - Endocrine toxicity of Cancer immunotherapy targeting immune checkpoints JO - Endocr Rev VL - 40 ID - Chang2019 ER - TY - JOUR AU - Johnson, D. B. AU - Manouchehri, A. AU - Haugh, A. M. PY - 2019 DA - 2019// TI - Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0617-x DO - 10.1186/s40425-019-0617-x ID - Johnson2019 ER - TY - JOUR AU - Min, J. AU - Osborne, V. AU - Kowalski, A. PY - 2018 DA - 2018// TI - Reported adverse events with painkillers: data mining of the US Food and Drug Administration adverse events reporting system JO - Drug Saf VL - 41 UR - https://doi.org/10.1007/s40264-017-0611-5 DO - 10.1007/s40264-017-0611-5 ID - Min2018 ER - TY - JOUR AU - Almenoff, J. S. AU - Pattishall, E. N. AU - Gibbs, T. G. PY - 2007 DA - 2007// TI - Novel statistical tools for monitoring the safety of marketed drugs JO - Clin Pharmacol Ther VL - 82 UR - https://doi.org/10.1038/sj.clpt.6100258 DO - 10.1038/sj.clpt.6100258 ID - Almenoff2007 ER - TY - JOUR AU - Ang, P. S. AU - Chen, Z. AU - Chan, C. L. PY - 2016 DA - 2016// TI - Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures JO - Expert Opin Drug Saf VL - 15 UR - https://doi.org/10.1517/14740338.2016.1167184 DO - 10.1517/14740338.2016.1167184 ID - Ang2016 ER - TY - JOUR AU - Hou, Y. F. AU - Ye, X. F. AU - Wu, G. Z. PY - 2014 DA - 2014// TI - A comparison of disproportionality analysis methods in national adverse drug reaction databases of China JO - Expert Opin Drug Saf VL - 13 UR - https://doi.org/10.1517/14740338.2014.915938 DO - 10.1517/14740338.2014.915938 ID - Hou2014 ER - TY - JOUR AU - Norén, G. N. AU - Hopstadius, J. AU - Bate, A. PY - 2013 DA - 2013// TI - Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery JO - Stat Methods Med Res VL - 22 UR - https://doi.org/10.1177/0962280211403604 DO - 10.1177/0962280211403604 ID - Norén2013 ER - TY - JOUR AU - Markham, A. AU - Duggan, S. PY - 2018 DA - 2018// TI - Cemiplimab: First Global Approval JO - Drugs. VL - 78 UR - https://doi.org/10.1007/s40265-018-1012-5 DO - 10.1007/s40265-018-1012-5 ID - Markham2018 ER - TY - JOUR AU - Filette, J. AU - Andreescu, C. E. AU - Cools, F. PY - 2019 DA - 2019// TI - A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors JO - Horm Metab Res VL - 51 UR - https://doi.org/10.1055/a-0843-3366 DO - 10.1055/a-0843-3366 ID - Filette2019 ER - TY - JOUR AU - Weber, J. S. AU - Postow, M. AU - Lao, C. D. PY - 2016 DA - 2016// TI - Management of Adverse Events Following Treatment with Anti-Programmed Death-1 agents JO - Oncologist VL - 21 UR - https://doi.org/10.1634/theoncologist.2016-0055 DO - 10.1634/theoncologist.2016-0055 ID - Weber2016 ER - TY - JOUR AU - Michot, J. M. AU - Bigenwald, C. AU - Champiat, S. PY - 2016 DA - 2016// TI - Immune-related adverse events with immune checkpoint blockade: a comprehensive review JO - Eur J Cancer VL - 54 UR - https://doi.org/10.1016/j.ejca.2015.11.016 DO - 10.1016/j.ejca.2015.11.016 ID - Michot2016 ER - TY - JOUR AU - Grassadonia, A. AU - Sperduti, I. AU - Vici, P. PY - 2018 DA - 2018// TI - Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced Cancer: a systematic review and meta-analysis of phase III randomized clinical trials JO - J Clin Med VL - 7 UR - https://doi.org/10.3390/jcm7120542 DO - 10.3390/jcm7120542 ID - Grassadonia2018 ER - TY - JOUR AU - Conforti, F. AU - Pala, L. AU - Bagnardi, V. PY - 2018 DA - 2018// TI - Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis JO - Lancet Oncol. VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30261-4 DO - 10.1016/S1470-2045(18)30261-4 ID - Conforti2018 ER - TY - JOUR AU - Morganstein, D. L. AU - Lai, Z. AU - Spain, L. PY - 2017 DA - 2017// TI - Thyroid Abnormalities following the use of CTLA-4 and PD-1 Inhibitors in the treatment of melanoma JO - Clin Endocrinol (Oxf) VL - 86 UR - https://doi.org/10.1111/cen.13297 DO - 10.1111/cen.13297 ID - Morganstein2017 ER - TY - JOUR AU - O'Connor, J. M. AU - Seidl-Rathkopf, K. AU - Torres, A. Z. PY - 2018 DA - 2018// TI - Disparities in the use of programmed death 1 immune checkpoint inhibitors JO - Oncologist. VL - 23 UR - https://doi.org/10.1634/theoncologist.2017-0673 DO - 10.1634/theoncologist.2017-0673 ID - O'Connor2018 ER - TY - JOUR AU - Rastrelli, M. AU - Tropea, S. AU - Rossi, C. R. PY - 2014 DA - 2014// TI - Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification JO - In vivo VL - 28 ID - Rastrelli2014 ER - TY - JOUR AU - Henley, S. J. AU - Richards, T. B. AU - Underwood, J. M. PY - 2014 DA - 2014// TI - Lung Cancer incidence trends among men and women — United States, 2005–2009 JO - MMWR Morb Mortal Wkly Rep VL - 63 ID - Henley2014 ER - TY - JOUR AU - Wang, D. Y. AU - Salem, J. E. AU - Cohen, J. V. PY - 2018 DA - 2018// TI - Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.3923 DO - 10.1001/jamaoncol.2018.3923 ID - Wang2018 ER - TY - JOUR AU - Boutros, C. AU - Tarhini, A. AU - Routier, E. PY - 2016 DA - 2016// TI - Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination JO - Nat Rev Clin Oncol VL - 13 UR - https://doi.org/10.1038/nrclinonc.2016.58 DO - 10.1038/nrclinonc.2016.58 ID - Boutros2016 ER - TY - JOUR AU - Ruggeri, R. M. AU - Campennì, A. AU - Giuffrida, G. PY - 2019 DA - 2019// TI - Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know) JO - J Endocrinol Investig VL - 42 UR - https://doi.org/10.1007/s40618-018-0984-z DO - 10.1007/s40618-018-0984-z ID - Ruggeri2019 ER - TY - JOUR AU - Raschi, E. AU - Mazzarella, A. AU - Antonazzo, I. C. PY - 2019 DA - 2019// TI - Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system JO - Target Oncol VL - 14 UR - https://doi.org/10.1007/s11523-019-00632-w DO - 10.1007/s11523-019-00632-w ID - Raschi2019 ER - TY - JOUR AU - Ott, P. A. AU - Hodi, F. S. AU - Robert, C. PY - 2013 DA - 2013// TI - CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0143 DO - 10.1158/1078-0432.CCR-13-0143 ID - Ott2013 ER - TY - JOUR AU - Grimaldi, A. M. AU - Marincola, F. M. AU - Ascierto, P. A. PY - 2016 DA - 2016// TI - Single versus combination immunotherapy drug treatment in melanoma JO - Expert Opin Biol Ther VL - 16 UR - https://doi.org/10.1517/14712598.2016.1128891 DO - 10.1517/14712598.2016.1128891 ID - Grimaldi2016 ER - TY - JOUR AU - Wolchok, J. D. AU - Chiarion-Sileni, V. AU - Gonzalez, R. PY - 2017 DA - 2017// TI - Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1709684 DO - 10.1056/NEJMoa1709684 ID - Wolchok2017 ER - TY - JOUR AU - Hammers, H. J. AU - Plimack, E. R. AU - Infante, J. R. PY - 2017 DA - 2017// TI - Safety and efficacy of Nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.72.1985 DO - 10.1200/JCO.2016.72.1985 ID - Hammers2017 ER - TY - JOUR AU - Hellmann, M. D. AU - Rizvi, N. A. AU - Goldman, J. W. PY - 2017 DA - 2017// TI - Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study JO - Lancet Oncol. VL - 18 UR - https://doi.org/10.1016/S1470-2045(16)30624-6 DO - 10.1016/S1470-2045(16)30624-6 ID - Hellmann2017 ER - TY - JOUR AU - Antonia, S. J. AU - López-Martin, J. A. AU - Bendell, J. PY - 2016 DA - 2016// TI - Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30098-5 DO - 10.1016/S1470-2045(16)30098-5 ID - Antonia2016 ER - TY - JOUR AU - Motzer, R. J. AU - Tannir, N. M. AU - McDermott, D. F. PY - 2018 DA - 2018// TI - Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1712126 DO - 10.1056/NEJMoa1712126 ID - Motzer2018 ER - TY - STD TI - Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;1. ID - ref33 ER - TY - JOUR AU - Osta, B. AU - Hu, F. AU - Sadek, R. PY - 2017 DA - 2017// TI - Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials JO - Crit Rev Oncol Hematol VL - 119 UR - https://doi.org/10.1016/j.critrevonc.2017.09.002 DO - 10.1016/j.critrevonc.2017.09.002 ID - Osta2017 ER - TY - JOUR AU - Khoja, L. AU - Day, D. AU - Wei-Wu Chen, T. PY - 2017 DA - 2017// TI - Tumor- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx286 DO - 10.1093/annonc/mdx286 ID - Khoja2017 ER - TY - JOUR AU - Callahan, M. K. AU - Wolchok, J. D. PY - 2013 DA - 2013// TI - At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy JO - J Leukoc Biol VL - 94 UR - https://doi.org/10.1189/jlb.1212631 DO - 10.1189/jlb.1212631 ID - Callahan2013 ER - TY - JOUR AU - Sznol, M. AU - Postow, M. A. AU - Davies, M. J. PY - 2017 DA - 2017// TI - Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management JO - Cancer Treat Rev VL - 58 UR - https://doi.org/10.1016/j.ctrv.2017.06.002 DO - 10.1016/j.ctrv.2017.06.002 ID - Sznol2017 ER - TY - JOUR AU - Abdel-Rahman, O. AU - ElHalawani, H. AU - Fouad, M. PY - 2016 DA - 2016// TI - Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis JO - Future Oncol VL - 12 UR - https://doi.org/10.2217/fon.15.222 DO - 10.2217/fon.15.222 ID - Abdel-Rahman2016 ER - TY - JOUR AU - Ji, H. H. AU - Tang, X. W. AU - Dong, Z. PY - 2019 DA - 2019// TI - Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS JO - Clin Drug Investig VL - 39 UR - https://doi.org/10.1007/s40261-018-0735-0 DO - 10.1007/s40261-018-0735-0 ID - Ji2019 ER - TY - JOUR AU - Barroso-Sousa, R. AU - Barry, W. T. AU - Garrido-Castro, A. C. PY - 2018 DA - 2018// TI - Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis JO - JAMA Oncol. VL - 4 UR - https://doi.org/10.1001/jamaoncol.2017.3064 DO - 10.1001/jamaoncol.2017.3064 ID - Barroso-Sousa2018 ER - TY - JOUR AU - Ryder, M. AU - Callahan, M. AU - Postow, M. A. PY - 2014 DA - 2014// TI - Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution JO - Endocr Relat Cancer VL - 21 UR - https://doi.org/10.1530/ERC-13-0499 DO - 10.1530/ERC-13-0499 ID - Ryder2014 ER -